# About Peptide Mundo — An Independent Metabolic Research Desk > About Peptide Mundo: an independent literature digest on three Metabolic & Weight Research incretin peptides. How it is compiled, what it covers, and what it is not — not a seller, not a clinic, not medical advice. An independent, citation-anchored digest of the incretin-agonist literature. Not a vendor. Not a clinic. Not medical advice. ## What Peptide Mundo is Peptide Mundo is an independent editorial reference desk covering the published research on three incretin-class peptides studied for **metabolic regulation and weight management**: semaglutide, tirzepatide, and retatrutide, with tirzepatide as the lead. The desk exists to make a rapidly expanding — and frequently overstated or misrepresented — literature legible: to tell a reader, in plain language and with citations, what each compound was actually studied for, in which populations, and how far that evidence honestly reaches. The organizing idea is the **incretin agonism ladder**: three compounds that progressively engage one, two, and three metabolic receptors. Reading them together gives a clearer picture than any one alone — you can see what the GLP-1 arm contributes, what adding GIP changes, and what the glucagon arm adds (and what remains unknown about it). Each compound has its own page; a comparison page lines them up side by side; and a single shared references list aggregates every source used across all three pages. Two of the three — semaglutide and tirzepatide — are approved prescription medicines with large, rigorous clinical trial programs. The third, retatrutide, is investigational. The desk treats all three with the same editorial discipline: it describes what was studied, how, in whom, and what was found, and it distinguishes between an FDA-approved indication and a Phase 2 finding from a 338-person trial. That distinction is not an afterthought; it is the whole point. ## How it is compiled Three principles govern what appears on this site. *First, every research claim is anchored to the peer-reviewed literature.* Each factual statement is tied to a numbered citation — PubMed-indexed journal articles, clinical-trial publications, and peer-reviewed reviews, with DOIs and PubMed links — collected on the [references page](/references). Where a finding comes from a review rather than a primary study, that distinction is noted. *Second, the evidence is described at its actual strength.* Results are reported in the populations and under the conditions in which they were studied — the SURMOUNT-5 result, for instance, is framed as a 72-week head-to-head trial in 751 adults with obesity, not a universal claim. Where a finding is Phase 2 only, or preclinical, or derived from a pharmacovigilance database rather than a controlled trial, this page says so. Where two sources disagree or a signal is unconfirmed, both sides of the question appear. *Third, the three compound pages are cross-referenced.* Because the same mechanisms — incretin receptor signaling, appetite suppression, GI motility, gallbladder risk, lean-mass loss — recur across all three compounds, the pages link to one another and to the comparison page, so a reader can follow a theme across the whole desk. ## What it is not Peptide Mundo is not a pharmacy, a clinic, a telehealth platform, or a vendor of any kind. It does not sell, supply, source, or broker any medicine or research chemical, and it has no affiliate or referral relationship with any pharmaceutical company, telehealth provider, or research-chemical vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person. Semaglutide and tirzepatide are approved prescription medicines available only through licensed medical providers. Retatrutide is not approved and should be discussed only in the context of registered clinical trials. Readers seeking clinical guidance should consult a licensed healthcare provider in their own jurisdiction, working with regulated, evidence-based options appropriate to their situation. Editorial correspondence on citation corrections, out-of-date references, or recently published studies can be directed to the [contact page](/contact). This desk monitors that correspondence carefully; it cannot respond to requests for medical advice. --- A peer-reviewed literature digest on incretin-class metabolic peptides — citations and context, not clinical counsel.